04.13.2016 | Investors

Allergan Announces 10 Presentations on Chronic Migraine, Upper and Lower Limb Spasticity and Alzheimer's Disease at the American Academy of Neurology Meeting in Vancouver

DUBLIN, April 13, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company today announced that it has 10 presentations at the upcoming 68th American Academy of Neurology (AAN) annual meeting taking place April 15-21, 2016 in Vancouver, Canada. Among the highlights are three platform presentations including post-stroke lower limb spasticity in adults.

Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO

"We are proud of the data being presented at AAN as it further demonstrates our leadership and commitment to research and development in neurology," said David Nicholson, executive vice president and president of Global R&D Brands at Allergan.

The scheduled times (noted in local Pacific Time) of the presentations and locations at the Vancouver Convention Centre are as follows:


  • "Muscle Selection Patterns for Injection of OnabotulinumtoxinA in Adult Patients With Post-Stroke Lower-Limb Spasticity Influence Outcome: Results From a Double-Blind, Placebo-Controlled Phase 3 Clinical Trial"
    • Presenter: Theodore Wein
    • Platform # 001, Session: S7: Stroke Clinical Trials
    • Sat, 4/16 3:30-3:45pm
  • "Sustained Benefit with Repeated Treatments of OnabotulinumtoxinA in Post-Stroke Lower Limb Spasticity: 1-Year Open-Label Final Results from a Double-Blind, Placebo-Controlled, Phase 3 Trial"
    • Presenter: Theodore Wein     
    • Platform # 002, Session: S7: Stroke Clinical Trials
    • Sat, 4/16 3:45-4:00pm
  • "Impact of Early Intervention With OnabotulinumtoxinA Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity"
    • Presenter: Atul Patel
    • Platform #006, Session: S31: Stroke Risk, Outcomes, and Complications
    • Tues, 4/19, 2:15-2:30pm
  • "Baseline Demographics and Clinical Characteristics of Patients Treated for Spasticity in the Adult Spasticity International Registry (ASPIRE Study)"
    • Authors: Francisco G, Bandari D, Bavikatte G, Jost W, Manack Adams A, Largent J, Esquenazi A           
    • Poster #296, Session: P3
    • Mon, 4/18, 8:30am-7pm (author attendance: 5:30-7 pm)

Chronic Migraine:

  • "Perspectives of Adolescents/Young Adults on the Burden of their Parent's Migraine: Results from the CaMEO Study"
    • Authors: Buse D, Powers S, Gelfand A, VanderPluym J, Fanning K, Reed M, Manack Adams A, Lipton R
    • Poster #121, Session: P4
    • Tues, 4/19, 8:30am-7pm (author attendance: 5:30-7pm)
  • "Family Impact of Migraine: Development of the Impact of Migraine on Partners and Children Scale (IMPACS)"
    • Authors: Lipton R,  Buse D, Manack Adams A, Varon, S, Fanning K, Reed ML
    • Poster # 172, Session: P1
    • Sat, 4/16, 8:30am-7pm (author attendance: 5:30-7pm)
  • "A Comparison Of The Chronic Migraine Epidemiology & Outcomes (CaMEO) Study And American Migraine Prevalence And Prevention (AMPP) Study: Demographics And Headache-Related Disability"
    • Authors: Buse D, Lipton R, Manack Adams A, Fanning K, Reed M
    • Poster # 167, Session: P1
    • Sat, 4/16, 8:30am-7pm (author attendance: 5:30-7pm)
  • "Real-World Utilization and Safety of OnabotulinumtoxinA for Chronic Migraine Headache Prophylaxis: Interim Analysis from an Observational Study in the European Union"
    • Authors: Matharu M, Pascual J, Nilsson Remahl I, Straube A, Johannes C, Odom D, Gutierrez L, Andrews E, Lum A
    • Poster  # 209, Session: P2
    • Sun, 4/17, 8:30am-5:30pm (author attendance: 4-5:30pm)

Alzheimer's Disease:

  • "Caregiver Distress Related to Neuropsychiatric Symptoms is Reduced with Extended-Release Memantine – Cholinesterase Inhibitor Combination in Patients with Moderate to Severe Alzheimer's Disease"
    • Authors: Atri A, Hendrix S, Ellison N, Otcheretko V, Edwards J
    • Poster # 219, Session: P2
    • Sun, 4/17, 8:30am-5:30pm (author attendance: 4-5:30pm)
  • "Daily Functioning Benefits of Adding Memantine to Stable Cholinesterase Treatment in Patients with Moderate to Severe Alzheimer's Disease: A Post Hoc Pooled Factor Analysis"
    • Authors: Alva G, Ellison N, Dass B, Hendrix S
    • Poster # 218, Session: P2
    • Sun, 4/17, 8:30am-5:30pm (author attendance: 4-5:30pm)

About Allergan
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.

Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry and a leading position in the submission of generic product applications globally.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives.

For more information, visit Allergan's website at www.allergan.com.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2015 (certain of such periodic public filings having been filed under the "Actavis plc" name). Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.


Lisa DeFrancesco
(862) 261-7152

Mark Marmur
(862) 261-7558

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/allergan-announces-10-presentations-on-chronic-migraine-upper-and-lower-limb-spasticity-and-alzheimers-disease-at-the-american-academy-of-neurology-meeting-in-vancouver-300248924.html

SOURCE Allergan plc

Media Contacts
Amy Rose
Global Corporate Media Relations
+1 (862) 289 3072
Lisa Brown
Global Corporate Media Relations
+1 (862) 261 7320
Fran DeSena
U.S. Product Media Relations
+1 (862) 261 8820
Mark Marmur
International Communications & Public Relations
+44 7725 758677

For local media contacts in other countries, please visit the relevant country website.

Investor relations:

Christine Chiou
Investor Relations
+1 (862) 261-7396